MedTrace Logo

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT04170998 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 283

Last updated 2021-12-10

No results posted yet for this study

Summary

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Conditions

  • Type2 Diabetes

Interventions

DRUG

Evogliptin 5mg

Participants receive Evogliptin 5mg orally once a day

DRUG

Evogliptin Placebo

Participants receive placebo to match Evogliptin 5mg orally once a day

DRUG

Dapagliflozin 10mg

Participants receive Dapagliflozin orally once a day

DRUG

Metformin ≥ 1000mg

Metformin are administered at the same dose and formulation.

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2021-06-28
Completion
2021-12-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170998 on ClinicalTrials.gov